Mark Cooper

Albert Einstein Juvenile Diabetes Research Foundation Centre for Diabetes Complications, Baker Medical Research Institute and Alfred Hospital, Australia

Any competing interests declared are displayed with individual evaluations.

Faculty Member: Nephrology > Pathophysiology of Chronic Kidney Disease (CKD) (since 08 May 2008)

All recent recommendations

• 10.4
  Effects of intensive blood-pressure control in type 2 diabetes mellitus.
  Recommended by Mark Cooper with David Barit, Ihab Wahba, Harald HHW Schmidt with Kirstin Wingler , Enyu Imai, William Mitch, Philip Gorelick with Rebbeca Grysiewicz, Fernando Testai
  
• 8.5
  Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study.
  Recommended by Sumio Hoka, Carmine Zoccali with Concetta Catalano and Giovanna Parlongo , Raymond Townsend, Mark Cooper with David Barit, Kazuomi Kario with Yuchiro Yano, Ole Skott with Pernille Hansen
  
• 6.9
  Aliskiren combined with losartan in type 2 diabetes and nephropathy.
  Recommended by Csaba Kovesdy, Jurg Schifferli with Michael Mayr, Rajiv Agarwal, Mai Ots-Rosenberg, Robert Anderson, Mark Cooper with David Barit
  
• 3.0
  Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial.
  Recommended by Mark Cooper with David Barit